Soleno Board Unanimously Recommends Shareholders Accept Neurocrine's $53.00/Share All-Cash Tender Offer

summarizeSummary

Soleno Therapeutics' Board of Directors unanimously recommends shareholders tender their shares in Neurocrine Biosciences' all-cash tender offer of $53.00 per share, citing a compelling premium and certainty of value amidst standalone risks.

check_boxKey Events

• Tender Offer Recommendation

  Soleno's Board of Directors unanimously recommends that shareholders accept Neurocrine Biosciences' tender offer to acquire all outstanding shares for $53.00 per share in cash.

• Significant Acquisition Premium

  The $53.00 per share offer represents a 34% premium over Soleno's closing price on April 2, 2026, and a 74% premium over the closing price on March 30, 2026, when Neurocrine made its 'best and final' offer.

• All-Cash Deal Provides Certainty

  The all-cash nature of the transaction offers immediate and certain value to shareholders, mitigating future market and operational risks for Soleno.

• Strategic Rationale Addresses Standalone Risks

  The Board's decision considered the risks of Soleno remaining an independent company, including its substantial dependence on VYKAT XR and the recent withdrawal of its European marketing application, making the acquisition a favorable outcome.

auto_awesomeAnalysis

This SC 14D9 filing provides Soleno Therapeutics' definitive recommendation to its shareholders regarding the tender offer by Neurocrine Biosciences. The Board's unanimous recommendation to accept the $53.00 per share all-cash offer is a significant positive for shareholders, offering a substantial premium over recent trading prices (e.g., 74% over the March 30, 2026 closing price). The decision was influenced by the certainty of an all-cash deal, the "best and final" nature of Neurocrine's offer, and the inherent risks of Soleno remaining an independent company, particularly following the recent withdrawal of its European marketing application for VYKAT XR. The transaction provides immediate liquidity and a clear exit at a favorable valuation, supported by fairness opinions from two financial advisors.